Equities Analysts Issue Forecasts for NTLA FY2029 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities researchers at Brookline Capital Management issued their FY2029 EPS estimates for Intellia Therapeutics in a note issued to investors on Monday, January 6th. Brookline Capital Management analyst L. Cann forecasts that the company will post earnings per share of $93.13 for the year. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.12) per share.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $0.03. The company had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. During the same quarter last year, the company posted ($1.38) EPS. The business’s revenue was down 24.1% compared to the same quarter last year.

Other analysts have also recently issued reports about the stock. Oppenheimer reduced their price objective on shares of Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating for the company in a research note on Monday, November 11th. Royal Bank of Canada reissued an “outperform” rating and set a $54.00 target price on shares of Intellia Therapeutics in a research report on Thursday, September 19th. Stifel Nicolaus lowered their price target on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a research report on Wednesday, September 11th. Wedbush reissued a “neutral” rating and set a $14.00 price objective on shares of Intellia Therapeutics in a research report on Monday, November 18th. Finally, StockNews.com raised Intellia Therapeutics to a “sell” rating in a report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Intellia Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $54.94.

Intellia Therapeutics Stock Down 2.6 %

Shares of Intellia Therapeutics stock opened at $12.47 on Wednesday. Intellia Therapeutics has a 12-month low of $11.34 and a 12-month high of $34.87. The stock has a 50 day moving average price of $14.01 and a two-hundred day moving average price of $19.28. The stock has a market capitalization of $1.27 billion, a P/E ratio of -2.29 and a beta of 1.83.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Elmwood Wealth Management Inc. grew its stake in shares of Intellia Therapeutics by 0.9% in the 3rd quarter. Elmwood Wealth Management Inc. now owns 67,774 shares of the company’s stock valued at $1,393,000 after purchasing an additional 600 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Intellia Therapeutics by 27.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock valued at $77,000 after buying an additional 794 shares in the last quarter. Capstone Investment Advisors LLC grew its position in Intellia Therapeutics by 1.4% in the third quarter. Capstone Investment Advisors LLC now owns 61,129 shares of the company’s stock valued at $1,256,000 after acquiring an additional 831 shares during the period. KBC Group NV raised its stake in Intellia Therapeutics by 37.3% during the third quarter. KBC Group NV now owns 3,753 shares of the company’s stock worth $77,000 after acquiring an additional 1,020 shares in the last quarter. Finally, Axxcess Wealth Management LLC raised its stake in Intellia Therapeutics by 5.4% during the third quarter. Axxcess Wealth Management LLC now owns 20,215 shares of the company’s stock worth $415,000 after acquiring an additional 1,044 shares in the last quarter. Institutional investors own 88.77% of the company’s stock.

Insider Buying and Selling at Intellia Therapeutics

In other news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 28,735 shares of company stock valued at $349,909 in the last 90 days. 3.20% of the stock is currently owned by company insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.